ArticleClinical, cosmetic and investigational dermatology2022

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.

Ying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.